Abstract Details

�鶹��ýӳ��

Abstract Details

Title The Effect of Serum ADMA Levels on Infarct Volume and Prognosis in Patients with Acute Ischemic Stroke

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) (-)

Poster/Presentation
Number 138

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
	No disclosure on file
Yahya Celik, MD (Trakya University Medical Faculty)	No disclosure on file
	No disclosure on file
	No disclosure on file
Talip Asil, MD (Gen Pharmaceuticals)	No disclosure on file
Michael Weller, MD (University Hospital Zurich)	Dr. Weller has received personal compensation in the range of $0-$499 for serving as a Consultant for Neurosense. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medac. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Philogen. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. Dr. Weller has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Curevac. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus. Dr. Weller has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novocure. The institution of Dr. Weller has received research support from Versameb.
Kevin E. Chapman, MD (Barrow Neurological Institute at Phoenix Children's Hospital)	No disclosure on file